Improved stability of a novel fluorine-18 labeled TCO analogue for pretargeted PET imaging.


Journal

Nuclear medicine and biology
ISSN: 1872-9614
Titre abrégé: Nucl Med Biol
Pays: United States
ID NLM: 9304420

Informations de publication

Date de publication:
Historique:
received: 06 09 2019
revised: 24 10 2019
accepted: 01 11 2019
pubmed: 11 11 2019
medline: 22 7 2020
entrez: 11 11 2019
Statut: ppublish

Résumé

Biorthogonal pretargeted imaging using the inverse electron demand Diels Alder (IEDDA) reaction between tetrazine (Tz) and trans-cyclooctene (TCO) is one of the most attractive strategies in molecular imaging. It allows the use of short-lived radioisotopes such as fluorine-18 for imaging of long circulating vectors with improved imaging contrast and reduced radiation dose. Here we aim to develop a novel We have synthetized a new TCO-analogue containing a 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA) chelator, allowing radiolabeling by chelation with aluminum fluoride (Al[ The radiotracer was obtained with a radiochemical yield (RCY) of 12.8 ± 2.8% and a radiochemical purity (RCP) of ≥95%. It also showed a promising in vivo stability with 51.9 ± 5.16% of radiotracer remaining intact after 1 h. The biodistribution in healthy mice demonstrated mixed hepatobiliary and renal clearance, with a rapid blood clearance and low uptake in other tissues. The low bone uptake indicated lack of tracer defluorination. Interestingly, a pretargeted PET imaging experiment showed a significantly increased radiotracer uptake (0.67 ± 0.16%ID/g, p < 0.001) in the tumors of mice pre-treated with CC49-tetrazine compared to the CC49 alone (0.16 ± 0.08%ID/g). [

Identifiants

pubmed: 31707309
pii: S0969-8051(19)30472-X
doi: 10.1016/j.nucmedbio.2019.11.001
pii:
doi:

Substances chimiques

Cyclooctanes 0
Fluorine Radioisotopes 0
Fluorine-18 GZ5I74KB8G

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

36-42

Informations de copyright

Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.

Auteurs

Eduardo Ruivo (E)

Laboratory of Medicinal Chemistry, University of Antwerp, Antwerp, Belgium. Electronic address: eduardo.ruivo@uantwerpen.be.

Karuna Adhikari (K)

Laboratory of Medicinal Chemistry, University of Antwerp, Antwerp, Belgium.

Filipe Elvas (F)

Laboratory of Medicinal Chemistry, University of Antwerp, Antwerp, Belgium; University Hospital Antwerp, Department of Nuclear Medicine, Edegem, Belgium; Molecular Imaging Center Antwerp, University of Antwerp, Antwerp, Belgium.

Jens Fissers (J)

Laboratory of Medicinal Chemistry, University of Antwerp, Antwerp, Belgium.

Christel Vangestel (C)

Molecular Imaging Center Antwerp, University of Antwerp, Antwerp, Belgium.

Steven Staelens (S)

Molecular Imaging Center Antwerp, University of Antwerp, Antwerp, Belgium.

Sigrid Stroobants (S)

University Hospital Antwerp, Department of Nuclear Medicine, Edegem, Belgium; Molecular Imaging Center Antwerp, University of Antwerp, Antwerp, Belgium.

Pieter Van der Veken (P)

Laboratory of Medicinal Chemistry, University of Antwerp, Antwerp, Belgium.

Leonie Wyffels (L)

University Hospital Antwerp, Department of Nuclear Medicine, Edegem, Belgium; Molecular Imaging Center Antwerp, University of Antwerp, Antwerp, Belgium.

Koen Augustyns (K)

Laboratory of Medicinal Chemistry, University of Antwerp, Antwerp, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH